JP2022537453A5 - - Google Patents

Info

Publication number
JP2022537453A5
JP2022537453A5 JP2021576300A JP2021576300A JP2022537453A5 JP 2022537453 A5 JP2022537453 A5 JP 2022537453A5 JP 2021576300 A JP2021576300 A JP 2021576300A JP 2021576300 A JP2021576300 A JP 2021576300A JP 2022537453 A5 JP2022537453 A5 JP 2022537453A5
Authority
JP
Japan
Prior art keywords
cancer
oncodriver
pulsed
combination therapy
dendritic cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021576300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537453A (ja
JP7579284B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038719 external-priority patent/WO2020257640A1/en
Publication of JP2022537453A publication Critical patent/JP2022537453A/ja
Publication of JP2022537453A5 publication Critical patent/JP2022537453A5/ja
Application granted granted Critical
Publication of JP7579284B2 publication Critical patent/JP7579284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021576300A 2019-06-21 2020-06-19 セマフォリン４ｄ遮断（ｓｅｍａ４ｄ）とｄｃ１療法との併用療法 Active JP7579284B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865027P 2019-06-21 2019-06-21
US62/865,027 2019-06-21
PCT/US2020/038719 WO2020257640A1 (en) 2019-06-21 2020-06-19 Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy

Publications (3)

Publication Number Publication Date
JP2022537453A JP2022537453A (ja) 2022-08-25
JP2022537453A5 true JP2022537453A5 (cg-RX-API-DMAC10.html) 2023-05-30
JP7579284B2 JP7579284B2 (ja) 2024-11-07

Family

ID=71575807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576300A Active JP7579284B2 (ja) 2019-06-21 2020-06-19 セマフォリン４ｄ遮断（ｓｅｍａ４ｄ）とｄｃ１療法との併用療法

Country Status (10)

Country Link
US (2) US11660330B2 (cg-RX-API-DMAC10.html)
EP (1) EP3986446B1 (cg-RX-API-DMAC10.html)
JP (1) JP7579284B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220044490A (cg-RX-API-DMAC10.html)
CN (1) CN114364399A (cg-RX-API-DMAC10.html)
AU (1) AU2020297592A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021025795A2 (cg-RX-API-DMAC10.html)
IL (1) IL288779B2 (cg-RX-API-DMAC10.html)
MX (1) MX2021015970A (cg-RX-API-DMAC10.html)
WO (1) WO2020257640A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240009232A1 (en) * 2020-08-21 2024-01-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy comprising her-2-dc1 vaccine and a probiotic
US20260232728A1 (en) * 2023-01-26 2026-08-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for identifying disseminated cancer cells in breast cancer patients
WO2024159105A1 (en) * 2023-01-26 2024-08-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of treating cancer comprising administration of intratumoral dcs in combination with systemic igg monoclonal antibody

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (cg-RX-API-DMAC10.html) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
EP2427212B1 (en) 2009-05-08 2017-08-23 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
US9243068B2 (en) 2013-06-25 2016-01-26 Vaccinex, Inc. Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases
JP2017512493A (ja) * 2014-03-14 2017-05-25 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復
US10574441B2 (en) * 2014-05-26 2020-02-25 Nokia Technologies Oy Management of cryptographic keys
CA2955445A1 (en) * 2014-07-17 2016-01-21 Brian J. Czerniecki Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
JP2018515421A (ja) 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造

Similar Documents

Publication Publication Date Title
Jain et al. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
Saif et al. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
JP4729503B2 (ja) 抗癌剤の奏効率増強剤
Gani et al. In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio
JP2013505223A5 (cg-RX-API-DMAC10.html)
US10987336B2 (en) Method of preventing or treating side effect of tumor therapy
JP2019501204A5 (cg-RX-API-DMAC10.html)
JP2008528486A5 (cg-RX-API-DMAC10.html)
JP2008501630A6 (ja) 抗癌剤の効果増強剤
JP2018537975A5 (cg-RX-API-DMAC10.html)
Zhu et al. Hydrogen inhibits the proliferation and migration of gastric cancer cells by modulating lncRNA MALAT1/miR-124-3p/EZH2 axis
JP2025185043A5 (cg-RX-API-DMAC10.html)
Bartelink et al. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours
CN105120663A (zh) 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物
JP2023512276A5 (cg-RX-API-DMAC10.html)
Irene et al. The emergence of targetable pathways in colorectal cancer
Du et al. Gantt chart for updated OS and PFS after cancer targeted therapy
Częścik et al. Evolution or revolution in colorectal cancer treatment: present and future of new therapeutic options. A narrative review
JP2014510047A5 (cg-RX-API-DMAC10.html)
Joensuu et al. A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer
NO20045249L (no) Epotilonderivat for behandling av hepatom og andre kreftsykdommer
RU2019134769A (ru) Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения
Freres et al. Categories of anticancer treatments
Ooi et al. RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update
Liu et al. Biomimetic anlotinib-loaded FePc-silicate nanoparticles for sonodynamic and immunotherapy in non-small cell lung cancer via dual PD-L1 modulation